Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
Jerry S. Wolinsky, Douglas L. Arnold, Bruno Brochet, Hans-Peter Hartung, Xavier Montalbán, Robert T. Naismith, Marianna Manfrini, James Overell, Harold Koendgen, Annette Sauter, Iain Bennett, Stanislas Hubeaux, Ludwig Kappos, Stephen L. Hauser
Topics & Concepts
OcrelizumabPost-hoc analysisOpen labelMedicinePlaceboTerm (time)Multiple sclerosisPost hocOratorioRandomized controlled trialInternal medicineAlternative medicinePsychiatryRituximabVisual artsMusicalLymphomaPhysicsPathologyArtQuantum mechanicsMultiple Sclerosis Research StudiesAmyotrophic Lateral Sclerosis ResearchPeripheral Neuropathies and Disorders